Among the recently investigated TKIs, Cediranib has been demonstrated to block tumor growth and to prolong survival in an ATC murine xenograft model showing high specificity for VEGFR1 and VEGFR2 inhibition resulting in an anti-angiogenic effect. Here, FLT1 is linked to neoplasm.